Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Flushing, Inappropriate schedule of product administration
Clinical narrative: Flushed in face and arm; metallic taste in mouth; prev_dose_administration_date=31/Jul/2021, dose_dose_number=1; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP and Physician) received via regulatory authority. The reporter is the patient.  A 48 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 08Oct2021 17:15 (Batch/Lot number: unknown) at the age of 48 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Allergy/Allergies" (unspecified if ongoing), notes: Yes many- Allergy tested before dose 2; "Hypothyroidism", start date: 31Jul2021 (unspecified if ongoing), notes: Chronic. Onset Time: Within 10min Ins. Outcome: Recovered; "Palpitations", start date: 31Jul2021 (unspecified if ongoing), notes: Chronic. Onset Time: Within 10min Ins. Outcome: Recovered; "Asthma", start date: 31Jul2021 (unspecified if ongoing), notes: Chronic. Onset Time: Within 10min Ins. Outcome: Recovered; "Migraines", start date: 31Jul2021 (unspecified if ongoing), notes: Chronic. Onset Time: Within 10min Ins. Outcome: Recovered; "Anxiety", start date: 31Jul2021 (unspecified if ongoing), notes: Chronic. Onset Time: Within 10min Ins. Outcome: Recovered; "Thyroid" (unspecified if ongoing); "GERD" (unspecified if ongoing); "Contraceptive" (unspecified if ongoing); "Vit D Def" (unspecified if ongoing); "Meniere's dis", start date: 31Jul2021 (unspecified if ongoing), notes: Chronic. Onset Time: Within 10min Ins. Outcome: Recovered; "Allergies rhinitis", start date: 31Jul2021 (unspecified if ongoing), notes: Chronic. Onset Time: Within 10min Ins. Outcome: Recovered. Concomitant medication(s) included: SYNTHROID taken for thyroid disorder (ongoing); RABEPRAZOLE taken for gastrooesophageal reflux disease (ongoing); SERTRALINE taken for anxiety (ongoing); ATENOLOL taken for palpitations (ongoing); FLUTICASONE taken for hypersensitivity (ongoing); LETIRIZINE taken for hypersensitivity (ongoing); MIRENA taken for intrauterine contraception (ongoing); VITAMIN D [COLECALCIFEROL] taken for vitamin d deficiency (ongoing). Vaccination history included: Bnt162b2 (Dose Number: 1, Lot Number: Unknown, Vaccine Location: Arm Right, Vaccine Administration Time: 10:00 AM, Route of administration: Intramuscular), administration date: 31Jul2021, when the patient was 48 years old, for Covid-19 Immunization. The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 08Oct2021, outcome "unknown", described as "prev_dose_administration_date=31/Jul/2021, dose_dose_number=1"; FLUSHING (non-serious) with onset 08Oct2021 17:15, outcome "recovered" (Oct2021), described as "Flushed in face and arm"; DYSGEUSIA (non-serious) with onset 08Oct2021 17:15, outcome "recovered" (Oct2021), described as "metallic taste in mouth". Therapeutic measures were not taken as a result of flushing, dysgeusia.  Additional information: The patient didn't receive any other vaccine within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. It was reported that Pfizer product had a causal effect to the adverse event.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.